Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics

Spero Therapeutics, Inc. (SPRO)

Today's Latest Price: $12.13 USD

0.19 (-1.54%)

Updated Jun 4 6:55pm

Add SPRO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SPRO Stock Summary

  • Spero Therapeutics Inc's stock had its IPO on November 2, 2017, making it an older stock than merely 7.75% of US equities in our set.
  • Of note is the ratio of Spero Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.49% of US stocks have a lower such ratio.
  • With a price/sales ratio of 20.6, Spero Therapeutics Inc has a higher such ratio than 93.44% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be AFMD, GRTS, TLC, ACIU, and UMRX.
  • SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Daily Price Range
SPRO 52-Week Price Range

SPRO Stock Price Chart More Charts

SPRO Price/Volume Stats

Current price $12.13 52-week high $14.38
Prev. close $12.32 52-week low $5.25
Day low $11.92 Volume 139,900
Day high $12.71 Avg. volume 132,350
50-day MA $10.21 Dividend yield N/A
200-day MA $10.11 Market Cap 249.82M

Spero Therapeutics, Inc. (SPRO) Company Bio

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.

SPRO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

SPRO Latest Social Stream

Loading social stream, please wait...

View Full SPRO Social Stream

Latest SPRO News From Around the Web

Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - June 4, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) ("Spero" or the "Company").Faruqi & Faruqi LogoIf you invested in Spero stock and would like to discuss your legal rights, click here: www.faruqilaw.com/SPRO. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free at 877-247-4292 ...

Yahoo | June 4, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO

Pomerantz LLP is investigating claims on behalf of investors of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. The investigation concerns whether Spero and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Yahoo | June 3, 2020

10 Tax Tips for Airbnb, HomeAway & VRBO Vacation Rentals

When you offer your home as a short-term rental through services like Airbnb, HomeAway, VRBO, and FlipKey you can keep your income taxes to a minimum.

Yahoo | June 2, 2020

Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

CAMBRIDGE, Mass., June 01, 2020 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

Yahoo | June 1, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2020 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

Yahoo | June 1, 2020

Read More 'SPRO' Stories Here

SPRO Price Returns

1-mo -0.25%
3-mo 32.14%
6-mo 1.59%
1-year 17.31%
3-year N/A
5-year N/A
YTD 26.16%
2019 56.34%
2018 -47.66%
2017 N/A
2016 N/A
2015 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9879 seconds.